Hypertensive Disorders of Pregnancy and Medication Use in the 2015 Pelotas (Brazil) Birth Cohort Study

Datos Bibliográficos

ID15495682
AutoresLisiane Freitas Leal (0000-0002-4151-8960, McGill University, autor de correspondencia), Sonia M Grandi (0000-0002-8576-7854, McGill University), Vanessa Iribarrem Avena Miranda (0000-0002-9156-5036, Universidade do Extremo Sul Catarinense), Tatiane Da Silva Dal Pizzol (0000-0002-7566-7745, Universidade Federal do Rio Grande do Sul), Robert W Platt (0000-0002-5981-8443, McGill University), Mariela Felisbino Da Silveira (0000-0002-2861-7139, Universidade Federal de Pelotas), Andréa Dâmaso Bertoldi (0000-0002-4680-3197, Universidade Federal de Pelotas)
Año2020
Volumen17
Número22
Páginas8541-8541
Fecha de publicación2020-11-18
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaInternational Journal of Environmental Research and Public Health (JOURNAL)
Identificadores de la revistaISSN: 1661-7827 • E-ISSN: 1660-4601
EditorialMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph17228541
PMID33217917
OpenAlexW3099538199
IdiomaEN
Citas recibidas4
Referencias citadas31

Hypertensive disorders of pregnancy account for approximately 22% of all maternal deaths in Latin America and the Caribbean. Pharmacotherapies play an important role in preventing and reducing the occurrence of adverse outcomes. However, the patterns of medications used for treating women with hypertensive disorders of pregnancy (HDP) living in this country is unclear. A population-based birth cohort study including 4262 women was conducted to describe the pattern of use of cardiovascular agents and acetylsalicylic acid between women with and without HDP in the 2015 Pelotas (Brazil) Birth Cohort. The prevalence of maternal and perinatal outcomes in this population was also assessed. HDP were classified according to Ministry of Health recommendations. Medications were defined using the Anatomical Therapeutic Chemical Classification System and the substance name. In this cohort, 1336 (31.3%) of women had HDP. Gestational hypertension was present in 636 (47.6%) women, 409 (30.6%) had chronic hypertension, 191 (14.3%) pre-eclampsia, and 89 (6.7%) pre-eclampsia superimposed on chronic hypertension. Approximately 70% of women with HDP reported not using any cardiovascular medications. Methyldopa in monotherapy was the most frequent treatment (16%), regardless of the type of HDP. Omega-3 was the medication most frequently reported by women without HDP. Preterm delivery, caesarean section, low birth weight, and neonatal intensive care admissions were more prevalent in women with HDP. Patterns of use of methyldopa were in-line with the Brazilian guidelines as the first-line therapy for HDP. However, the large number of women with HDP not using medications to manage HDP requires further investigation

Blood pressure · Cohort · Cohort study · Eclampsia · Environmental health · Gestational hypertension · Low birth weight · Methyldopa · Obstetrics · Population · Preeclampsia · Pregnancy · Prenatal care · Birth, Development, and Health · Maternal and fetal healthcare · Medicine · Pregnancy and preeclampsia studies · Internal Medicine · Pediatrics